Dissecting Aneurysm of Cerebral Artery Clinical Trial
Official title:
Investigation of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Analysis Predicting Prognosis of Intracranial Dissecting Aneurysm With Intramural Hematoma After Endovascular Treatment
This study will evaluate the feasibility to predict the prognosis of IDA with IMH by DCE-MRI and provide theoretical basis for the prognosis and intervention of the disease.
Intracranial dissecting aneurysm (IDA) was a challenging disease and could result in stroke
in young and middle-aged adults. Intramural hematoma, one of the typical imaging findings of
IDA, can grow continuously in untreated IDA. Due to relatively high complication rate
associated with surgical procedures, endovascular treatments have become the first-line
therapy for such lesions. According to whether the parent artery was maintained, endovascular
treatment was divided into deconstructive (proximal arterial occlusion and internal trapping)
and reconstructive (stent implantation with or without coiling) techniques . However,
recanalization of IDA was a great challenge for endovascular treatment and influenced the
prognosis of patients.
The formation of an IMH is a critical event in the progress of IDA and IDA may grow because
of recurrent IMH even after deconstructive endovascular treatment. Increased IMH size could
result in severe compression symptoms or even death. At present, the mechanism of the
continuous growth of intramural hematoma after endovascular treatment of IDA is still
unclear. Some authors believe that the continuous hemorrhage of the vasa vasorum in the IMH
results in the continuous enlargement of the IMH. However, this theory has not been proved by
imaging in vivo.
Dynamic contrast-enhanced magnetic resonance imaging analysis for prognosis of intracranial
dissecting aneurysm with intramural hematoma after endovascular treatment (DEMAT) is a
prospective trial designed to collect a large series of patients with IDAs treated
endovascularly to predict the prognosis of IDA with IMH by DCE-MRI and provide theoretical
basis for the prognosis and intervention of the disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06405971 -
Metformin in Patients With Unruptured Vertebrobasilar Dissecting Aneurysms (METTLE)
|
N/A | |
| Recruiting |
NCT04943783 -
Atorvastatin in the TREATment of Intracranial Unruptured VertebroBasilar Dissecting Aneurysms
|
N/A | |
| Recruiting |
NCT02914288 -
Prospective Observation for Serial Changes of Acute Intracranial Artery Dissection Using High Resolution MRI
|
N/A |